Cognition Therapeutics is a privately held biopharmaceutical company focused on the creation and clinical development of a pipeline of disease-modifying small molecule drug candidates that stop neurological disease processes and restore and preserve the building blocks of brain health and function: the synapse. Cognition’s lead candidate, CT1812, is a proprietary first-in-class, orally dosed & highly brain penetrant small mo...
Cognition Therapeutics is a privately held biopharmaceutical company focused on the creation and clinical development of a pipeline of disease-modifying small molecule drug candidates that stop neurological disease processes and restore and preserve the building blocks of brain health and function: the synapse. Cognition’s lead candidate, CT1812, is a proprietary first-in-class, orally dosed & highly brain penetrant small molecule in development for treatment of mild-to-moderate Alzheimer’s disease. A significant body of genetic and clinical evidence points to accumulation of Aβ as the central pathogenic cause of Alzheimer’s disease.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.